EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review

Artur Macedo Cruz, Bruna Carolyne Venancio Lima, José Erivelton Souza Maciel de Ferreira, Rian Brito Teles

European Journal of Clinical Pharmacology · 2026-07 · 82 (7)

DOI: 10.1007/s00228-026-04095-7 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 10.06.2026. Verfasst von Artur Macedo Cruz und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Gurupi, Gurupi, Tocantins, Brazil. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Incretins, Fatty Liver, Metabolic Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade Da Integracao Internacional Da Lusofonia Afro Brasileira.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In recent years, metabolic therapies originally developed to treat systemic metabolic disorders have been investigated as potential therapeutic strategies for Metabolic dysfunction-associated steatohepatitis (MASH).

Objective

This study aimed to critically evaluate recent clinical evidence on emerging metabolic therapies, particularly sodium-glucose cotransporter-2 (SGLT2) inhibitors and incretin-based agents, examining their effects on hepatic and metabolic outcomes and, when available, histological endpoints, as well as safety in patients with MASH.

Methods

A systematic review of clinical studies evaluating metabolic therapies in patients with MASH or metabolically associated fatty liver disease was conducted. Randomized clinical trials and other relevant clinical studies investigating SGLT2 inhibitors, incretin-based therapies, and other emerging metabolic agents were included. Outcomes of interest comprised metabolic parameters, hepatic outcomes related to steatosis and disease activity, and histological endpoints when available.

Results

Twelve clinical studies were included. In trials with histological endpoints, semaglutide achieved steatohepatitis resolution without worsening of fibrosis in 62.9% versus 34.3% with placebo in a phase 3 trial ( p < 0.001), while a phase 2 trial reported NASH resolution in 59% versus 17% with placebo ( p < 0.001), without significant fibrosis improvement (43% versus 33%; p = 0.48). Tirzepatide achieved MASH resolution without worsening of fibrosis in 44–62% of patients versus 10% with placebo ( p < 0.001 for all doses), and fibrosis improvement in 51–55% versus 30%. Among SGLT2 inhibitors, dapagliflozin achieved MASH improvement without worsening of fibrosis in 53% versus 30% ( p = 0.006), MASH resolution in 23% versus 8% ( p = 0.01), and fibrosis improvement in 45% versus 20% ( p = 0.001). Overall, metabolic therapies improved body weight, hepatic steatosis, glycemic parameters, and disease activity, but evidence for durable fibrosis regression and long-term liver-related outcomes remains heterogeneous.

Conclusion

Emerging metabolic therapies show promising effects on metabolic and hepatic outcomes in patients with MASH. Incretin-based therapies appear to exert particularly robust effects on body weight reduction and steatohepatitis resolution, whereas SGLT2 inhibitors may provide complementary metabolic, cardiometabolic, and hepatic benefits. Nevertheless, fibrosis-related effects remain less consistent across studies, and future trials with paired histological endpoints, longer follow-up, and clinically meaningful liver-related outcomes are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsIncretinsFatty LiverMetabolic DiseasesHumansSemaglutide

Stichwörter der Autor:innen

Glucagon-Like Peptide-1 Receptor AgonistsInsulin ResistanceMetabolic DiseasesMetabolic dysfunction-associated steatohepatitisSodium-Glucose Transporter 2 Inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsIncretinsSemaglutide

Autor:innen und Institutionen

  • University of Gurupi, Gurupi, Tocantins, Brazil.
  • Medical Residency in Internal Medicine, Idomed Quixadá, Ceará, Brazil.
  • Estácio Faculty of Medicine of Juazeiro do Norte, Ceará, Brazil.
  • Federal University of Cariri, Ceará, Brazil.
  • University for the International Integration of the Afro-Brazilian Lusophony (UNILAB), Ceará, Brazil. eriveltonsmf@aluno.unilab.edu.br.
  • Abelardo Gadelha da Rocha Municipal Hospital, Caucaia, Ceará, Brazil. eriveltonsmf@aluno.unilab.edu.br.

Förderung

  • Universidade Da Integracao Internacional Da Lusofonia Afro Brasileira

Zitieren

APA

Cruz, A. M., Lima, B. C. V., de Ferreira, J. E. S. M., & Teles, R. B. (2026). SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review. European Journal of Clinical Pharmacology, 82(7). https://doi.org/10.1007/s00228-026-04095-7

Vancouver

Cruz AM, Lima BCV, de Ferreira JESM, Teles RB. SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review. European Journal of Clinical Pharmacology. 2026;82(7). doi:10.1007/s00228-026-04095-7

BibTeX
@article{Cruz2026,
  author = {Cruz, Artur Macedo and Lima, Bruna Carolyne Venancio and de Ferreira, José Erivelton Souza Maciel and Teles, Rian Brito},
  title = {SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {7},
  doi = {10.1007/s00228-026-04095-7}
}
Kostenlos starten →